Prior to the development of calcitonin gene-related peptide (CGRP) pathway–targeted monoclonal antibodies (CGRP mAbs), medications available for migraine prevention were not specifically “targeted” to migraine and were generally underused, associated with poor tolerability, insufficient efficacy, and/or demonstrated very low rates of adherence and persistence [2]. The gene discussed is CALCA; the disease is migraine disorder.